Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $213.00 by Analysts at Bank of America

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective upped by Bank of America from $166.00 to $213.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on SRPT. Barclays boosted their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an overweight rating in a research report on Thursday, February 29th. UBS Group boosted their price target on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a buy rating in a research report on Friday, March 1st. TheStreet upgraded shares of Sarepta Therapeutics from a d rating to a c- rating in a report on Monday, March 4th. Citigroup boosted their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a buy rating in a report on Thursday, February 29th. Finally, Mizuho boosted their target price on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a buy rating in a report on Friday, May 17th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $177.65.

Sarepta Therapeutics Stock Up 30.1 %

SRPT stock opened at $160.72 on Friday. The stock has a market capitalization of $15.19 billion, a P/E ratio of 1,461.09 and a beta of 0.96. The firm has a 50-day simple moving average of $125.56 and a 200-day simple moving average of $119.73. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. Sarepta Therapeutics’s quarterly revenue was up 63.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.44) earnings per share. Equities analysts forecast that Sarepta Therapeutics will post 2.99 earnings per share for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In related news, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the business. Capital Fund Management S.A. purchased a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $7,299,000. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after buying an additional 41,465 shares during the period. Principal Financial Group Inc. increased its stake in Sarepta Therapeutics by 125.3% during the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after buying an additional 27,549 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $777,000. Finally, Great Point Partners LLC increased its position in shares of Sarepta Therapeutics by 14.0% in the 4th quarter. Great Point Partners LLC now owns 80,000 shares of the biotechnology company’s stock valued at $7,714,000 after purchasing an additional 9,800 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.